Therapeutics

© Reuters. Tuesday, AN2 Therapeutics (NASDAQ:ANTX) received a rating downgrade from Leerink Partners from Outperform to Market Perform with a significant reduction in the price target to $7.00 from the previous $23.00. The downgrade…

This section is Partnership Content suppliedThe content in this section is supplied by GlobeNewswire for the purposes of distributing press releases on behalf of its clients. Postmedia has not reviewed the content. by GlobeNewswire…

This section is Partnership Content suppliedThe content in this section is supplied by Business Wire for the purposes of distributing press releases on behalf of its clients. Postmedia has not reviewed the content. by Business Wire…

© Reuters. Explore Wall Street's expert insights with this ProResearch article, which will exclusively be available to InvestingPro subscribers soon. Enhance your investment strategy with ProPicks, our newest product featuring…

This section is Partnership Content supplied The content in this section is supplied by GlobeNewswire for the purposes of distributing press releases on behalf of its clients. Postmedia has not reviewed the content.…

Alexey Krukovsky Leerink said Friday that it believes Structure Therapeutics (NASDAQ:GPCR) shares are “significantly undervalued” given the “extraordinary” total addressable market for oral GLP-1 diabetes drugs. The investment bank…

© Reuters. FILE PHOTO: An Amgen sign is seen at the company's office in South San Francisco, California October 21, 2013. REUTERS/Robert Galbraith/File Photo (Reuters) -The U.S. Federal Trade Commission (FTC) has suspended its…

Article content NEW YORK, June 30, 2023 (GLOBE NEWSWIRE) -- Athyrium Capital Management, LP announces that the funds it manages have sold a total of 1,300,000 common shares of HLS Therapeutics ("institution’) on the facilities of the…

Sigilon Therapeutics Inc (NASDAQ:SGTX) shares rallied after that Eli Lilly and Company (NYSE: LLY) has agreed to acquire the company at a purchase price of $14.92 per share in cash (for a total of about $34.6 million).Sigilon is also…

Eli Lilly will spend nearly $2.4 billion to acquire Dice Therapeutics to create more drugs to combat autoimmune diseases. American pharmaceutical company Eli Lilly has announced that it intends to buy biopharmaceutical company Dice…